Last reviewed · How we verify
Keytruda — dosage & administration
Pembrolizumab blocks PD-1 receptor, releasing immune inhibition and enhancing anti-tumor T-cell response.
Administration
| Route | Subcutaneous |
|---|---|
| Formulation | Injection |
Consult the full prescribing information for clinical dosing. This page is research context, not medical advice.
See also
- Full profile: Keytruda
- Side effects: /side-effects
- Mechanism of action: /mechanism
- Cost & pricing: /cost
- Drug interactions: /interactions
- Clinical trials: /clinical-trials
- Patents & exclusivity: /patents
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing